Decoglurant
 | |
| Clinical data | |
|---|---|
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | 911115-16-7 |
| PubChem (CID) | 71533696 |
| ChemSpider | 32695160 |
| Chemical and physical data | |
| Formula | C21H11F6N5 |
| Molar mass | 447.336 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.[1][2] Decoglurant progressed as far as phase II clinical trials[1][2] but was ultimately discontinued from further development due to disappointing efficacy results.[3][4]
See also
References
- 1 2 "Roche - Pipeline". 2014. Retrieved 2014-08-01.
- 1 2 "Roche Group Development Pipeline" (PDF). 2014. Retrieved 2014-08-01.
- ↑ "Roche - Pipeline" (PDF). 2015. Retrieved 2015-05-14.
- ↑ Janna Lawrence (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal.
External links
This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.